A novel strategy for addressing inflammatory diseases via customized probiotic therapies—commonly referred to as precision medicine—has been introduced by researchers.
Researchers at the University of Surrey have introduced a new strategy for treating inflammatory diseases using customized probiotic therapies, often known as precision medicine.
The human gut microbiome is a sophisticated system of bacteria that is essential for maintaining overall health. Disruptions in this system, referred to as dysbiosis, have been associated with a range of inflammatory disorders.
By utilizing extensive computer models like Genome Scale Metabolic Models (GSMMs) and analytical techniques such as Flux Balance Analysis (FBA), researchers are able to explore the complexity of the human gut microbiome. Analyzing these models allows scientists to pinpoint potential targets and create tailored probiotic and prebiotic therapies.
Dr. Matteo Barberis, the primary author of the study and a Reader in Systems Biology at the University of Surrey, states:
“Our study introduces a workflow that models interactions within the human gut microbiome for the purpose of probiotic development. This is a significant advancement, providing a fresh approach to treating inflammatory diseases. It is capable of predicting metabolic activities among the bacterial strains present in the gut, which may be manipulated to restore balance and facilitate dietary or probiotic interventions. By gaining insights into the complex dynamics of the gut microbiome and establishing specialized modeling workflows, we are setting the stage for a future where personalized treatments can enhance patient well-being.”
